97 related articles for article (PubMed ID: 4040542)
21. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
Kobayashi H; Hayata T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
[TBL] [Abstract][Full Text] [Related]
22. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
23. The value of tubular enzymes for early detection of acute kidney injury after liver transplantation: an observational study.
Santos C; Marcelino P; Carvalho T; Coelho J; Bispo M; Mourão L; Perdigoto R; Barroso E
Transplant Proc; 2010 Nov; 42(9):3639-43. PubMed ID: 21094831
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
Ehrlich CE; Einhorn L; Williams SD; Morgan J
Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
[No Abstract] [Full Text] [Related]
25. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
[TBL] [Abstract][Full Text] [Related]
26. [Study on urinary gamma-GTP activities as an indicator of cis-diamminedichloride platinum nephrotoxicity].
Takahashi T; Yoshida K; Nakame Y; Saitoh H
Hinyokika Kiyo; 1986 Jun; 32(6):789-94. PubMed ID: 2876605
[TBL] [Abstract][Full Text] [Related]
27. The sensitivity of urinary enzyme measurements for detecting renal injury.
Plummer DT; Ngaha EO; Wright PJ; Leathwood PD; Blake ME
Curr Probl Clin Biochem; 1979; (9):71-87. PubMed ID: 446087
[TBL] [Abstract][Full Text] [Related]
28. [Hypomagnesemia following chemotherapy of disseminated testicular tumors].
Hida S; Nishimura K; Nishio Y; Okada Y; Okada K; Yoshida O
Hinyokika Kiyo; 1988 Jan; 34(1):52-60. PubMed ID: 2454015
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma.
Decker DG; Fleming TR; Malkasian GD; Webb MJ; Jeffries JA; Edmonson JH
Obstet Gynecol; 1982 Oct; 60(4):481-7. PubMed ID: 6889714
[TBL] [Abstract][Full Text] [Related]
30. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury.
Saleh S; Ain-Shoka AA; El-Demerdash E; Khalef MM
Chemotherapy; 2009; 55(6):399-406. PubMed ID: 19955745
[TBL] [Abstract][Full Text] [Related]
31. [The effect on prognosis and the adverse drug reaction of intermittent cisplatin therapy in advanced ovarian cancer patients].
Umesaki N; Matsumoto Y; Nakano M; Kawabata M; Sugawa T
Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2758-66. PubMed ID: 2074385
[TBL] [Abstract][Full Text] [Related]
32. Endotoxin-induced alterations in renal function with particular reference to tubular enzyme activity.
Rao PS; Cavanagh DM; Fiorica JV; Spaziani E
Circ Shock; 1990 Jul; 31(3):333-42. PubMed ID: 2357774
[TBL] [Abstract][Full Text] [Related]
33. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
34. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
Sato J; Kudo K; Hino K; Takahashi K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
[TBL] [Abstract][Full Text] [Related]
35. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of renal enzymuria and cellular excretion as an marker of acute nephrotoxicity due to an overdose of paracetamol in Wistar rats.
da Silva Melo DA; Saciura VC; Poloni JA; Oliveira CS; Filho JC; Padilha RZ; Reichel CL; Neto EJ; Oliveira RM; D'avila LC; Kessler A; de Oliveira JR
Clin Chim Acta; 2006 Nov; 373(1-2):88-91. PubMed ID: 16806140
[TBL] [Abstract][Full Text] [Related]
37. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
38. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
39. Use of cis-platinum in the treatment of ovarian carcinoma. Clinical results and evaluation of nephrotoxicity.
Giannattasio M; Rizzi R; Coratelli P; Restaino A; Selvaggi L; Ferreri R; Orlando E; Ierardi GM; Granata A; Bettocchi S
Eur J Gynaecol Oncol; 1983; 4(1):41-3. PubMed ID: 6407837
[No Abstract] [Full Text] [Related]
40. [Increase in CDDP therapeutic index by lower concentration and longer infusion time--home chemotherapy for ovarian cancer].
Chen JT; Tatsuki Y; Hirai Y; Hasumi K
Gan To Kagaku Ryoho; 1993 Feb; 20(2):265-70. PubMed ID: 8434965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
